Patients with PAH have reduced ACE2 expression and a pilot study demonstrated that recombinant protein infusion improved PVR and cardiac output and reduced oxidative stress and inflammatory mediators; a phase-2 trial is currently recruiting for PAH patients [99,100]. The gene discussed is ACE2; the disease is pulmonary arterial hypertension.